EACS 2025 was an essential meeting for the numerous presentations about PrEP that included far more than news about injectable formulations, which for all their promise, are still hardly utilized by anyone.
Cabotegravir-LA (CAB-LA) and lenacapavir (LEN) are important of course, but the most sobering results related to the current limited access to oral PrEP, reported in a plenary lecture by Teymur Noori from the ECDC on Europe’s uncertain health tarreceives.
Ten years after FTC/TDF was approved by the EMA, PrEP is only being widely utilized in a few countries, with many barriers and inequalities even to low-priced generics.
These details necessary to be taken toreceiveher with the announcement that the EACS guidelines now support event-based dosing for everyone.
Read the full news story at HIV i-Base.
Leave a Reply